Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H.

AIDS. 1995 Mar;9(3):223-8. Unique Identifier : AIDSLINE MED/95275455
Chan WL; Rodgers A; Grief C; Almond N; Ellis S; Flanagan B; Silvera P; Bootman J; Stott J; Kent K; et al; National Institute for Biological Standards and Control, South; Mimms, Potters Bar, UK.

Abstract: OBJECTIVE: To evaluate the efficacy of immunopurified class I human histocompatibility leukocyte antigen (HLA) to protect against SIV infection. METHODS: HLA class I antigens were immunopurified from a human B-lymphoblastoid cell line. Groups of four macaques were vaccinated subcutaneously with four doses of the immunogen in adjuvant, or with adjuvant alone and subsequently challenged intravenously with 10 median monkey infectious doses of cell-free SIVmac-32H. Infection was determined by polymerase chain reaction for SIVmac proviral DNA and by virus isolation. Antigen-specific humoral and cellular immune responses were monitored. RESULTS: Macaques immunized with the HLA molecules produced anti-HLA class I antibodies that inhibited SIV replication in vitro and downregulated autologous T-cell proliferation against irradiated C8166 cells. They were partially protected (two out of four) from virus infection for at least 33 weeks when challenged with SIV grown in human cells. All four control animals were infected. CONCLUSIONS: This demonstration of partial protection, together with our previous work reporting that vaccination with allogenic cynomolgus lymphocytes can protect against challenge infection with SIV grown in simian cells, suggests that allogenic immune response induced before or during establishment of HIV infection may have important implications for AIDS disease progression.

Keywords: Animal Antibodies, Viral/BIOSYNTHESIS Down-Regulation (Physiology) Histocompatibility Antigens Class I/ANALYSIS/*IMMUNOLOGY/ ISOLATION & PURIF Human Immunity, Cellular Lymphocyte Transformation Macaca fascicularis Simian Acquired Immunodeficiency Syndrome/*PREVENTION & CONTROL Support, Non-U.S. Gov't SIV/IMMUNOLOGY/PHYSIOLOGY T-Lymphocytes/IMMUNOLOGY Vaccination Virion/CHEMISTRY Virus Replication JOURNAL ARTICLE
950930
M9591005

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .